MRNA Stock Price: Moderna hits record high amid coronavirus vaccine progress, new test underway

  • NASDAQ: MRNA shares are set to jump to around $85, a record high.
  • Moderna Inc reported progress in its COVID-19 vaccine efforts 
  • Broader stock markets are also on the rise in the hopes of a broad turnaround.

Moderna Inc. (MRNA) is trading around $87, the highest on record and above the previous peak in May. The company has been at the forefront of efforts to develop immunization for the disease that is gripping the world and is now benefiting from progress as the trial produces a "robust immune response". 

MRNA Stock News

The prestigious New England Journal of Medicine reported details about Moderna's vaccine efforts. The Massachusetts-based pharmaceutical firm tested its candidate on 45 humans, which all showed a robust amount of antibodies – as much as four times the level seen in recovered coronavirus patients. 

Moreover, side-effects were minimal among those that were tested, showing the vaccine is safe. There still is a long road to approving, producing, and administering a vaccine to the globe's population is still long. Moderna's next step is a broad test of 30,000 people.

Contrary to the previous publication – when Moderna only issued a press release – the publication by the highly regarded magazine is already applauded by the medical community. 

It is essential to note that other efforts are in play, most notably cooperation between the University of Oxford and AstraZeneca. 

The S/P 500 has turned positive for the year, boosted by the NASDAQ: MRNA news. 

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.

Feed news

Latest Forex News

Latest Forex News

Editors’ Picks

EUR/USD hits the highest in a month on stimulus hopes

EUR/USD has advanced toward 1.1850, reaching the highest since mid-September. US lawmakers have reportedly narrowed the gap in stimulus talks. The safe-haven dollar is on the back foot and investors are shrugging off concerns about new European COVID-19 cases.


GBP/USD bounces on better market mood

GBP/USD has recaptured the 1.2950 level after a call between Brexit negotiators was labeled as constructive. PM Johnson is set to put the Greater Manchester area under lockdown and US fiscal stimulus talks are eyed.


XAU/USD struggles for direction, stuck in a range near $1900 mark

Gold extended its sideways consolidative price moves through the early North American session and remained confined in a narrow trading band, around the $1900 mark.

Gold News

US Markets React: Gold gains, equities and dollar tumble on stimulus jitters

The stimulus election minute, the most popular dance in Washington, went through another few elaborate rounds on Capitol Hill today with Nancy Pelosi's office reporting progress in afternoon talks with Steven Mnuchin.

Read more

WTI extends the consolidation around $40.00 ahead of API

Prices of the barrel of WTI extend the consolidative mood for yet another session on Tuesday, always around the key $40.00 level.

Oil News